
HLS Therapeutics Inc
TSX:HLS

Intrinsic Value
The intrinsic value of one
HLS
stock under the Base Case scenario is
6.19
CAD.
Compared to the current market price of 4.8 CAD,
HLS Therapeutics Inc
is
Undervalued by 22%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
HLS Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
HLS Therapeutics Inc
Balance Sheet Decomposition
HLS Therapeutics Inc
Current Assets | 34.1m |
Cash & Short-Term Investments | 17.7m |
Receivables | 7.8m |
Other Current Assets | 8.5m |
Non-Current Assets | 119.9m |
PP&E | 972k |
Intangibles | 117.2m |
Other Non-Current Assets | 1.7m |
Free Cash Flow Analysis
HLS Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
HLS Therapeutics Inc
Revenue
|
56.8m
USD
|
Cost of Revenue
|
-9.6m
USD
|
Gross Profit
|
47.1m
USD
|
Operating Expenses
|
-51.8m
USD
|
Operating Income
|
-4.6m
USD
|
Other Expenses
|
-13.3m
USD
|
Net Income
|
-18m
USD
|
HLS Profitability Score
Profitability Due Diligence
HLS Therapeutics Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Score
HLS Therapeutics Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
HLS Solvency Score
Solvency Due Diligence
HLS Therapeutics Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.

Score
HLS Therapeutics Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HLS Price Targets Summary
HLS Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
HLS
is 6.27 CAD
with a low forecast of 4.04 CAD and a high forecast of 9.98 CAD.
Dividends
Current shareholder yield for HLS is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
HLS
stock under the Base Case scenario is
6.19
CAD.
Compared to the current market price of 4.8 CAD,
HLS Therapeutics Inc
is
Undervalued by 22%.